

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q2 13-14</b>	<b>Q2 12-13</b>	<b>% Gr y-y</b>	<b>YTD 13-14</b>	<b>YTD 12-13</b>	<b>% Gr y-y</b>
<b>Domestic</b>	<b>7,997</b>	<b>7,635</b>	<b>4.8%</b>	<b>16093</b>	<b>15087</b>	<b>6.7%</b>
Formulations	6,263	6,016	4.1%	12,515	11,832	5.8%
API	119	116	2.6%	319	224	42.4%
Wellness	1,039	965	7.7%	2,189	1,998	9.5%
Animal Health & Others	576	538	7.0%	1,070	1,033	3.6%
<b>Exports</b>	<b>8,310</b>	<b>6,498</b>	<b>27.9%</b>	<b>15,370</b>	<b>13,216</b>	<b>16.3%</b>
Formulations	<b>7,438</b>	<b>5,808</b>	<b>28.1%</b>	<b>13,710</b>	<b>11,760</b>	<b>16.6%</b>
US	4,730	3,674	28.8%	8,605	7,266	18.4%
Europe	942	762	23.6%	1,870	1,617	15.7%
Japan	131	143	-8.8%	252	282	-10.6%
Brazil	622	487	27.9%	1,142	1,131	0.9%
Mexico	32	0		36	0	
Emerging Mkts & Others	981	742	32.1%	1,806	1,464	23.4%
API	<b>738</b>	<b>588</b>	<b>25.5%</b>	1,396	1,238	<b>12.8%</b>
Animal Health & Others	<b>134</b>	<b>102</b>	<b>31.7%</b>	264	218	<b>21.0%</b>
<b>JVs</b>	<b>1,068</b>	<b>1,314</b>	<b>-18.7%</b>	<b>2,375</b>	<b>2,610</b>	<b>-9.0%</b>
<b>Total</b>	<b>17,375</b>	<b>15,447</b>	<b>12.5%</b>	<b>33,838</b>	<b>30,913</b>	<b>9.5%</b>

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q2 13-14	Q2 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Other Operating Income</b>	<b>486</b>	<b>351</b>	<b>38.4%</b>	<b>782</b>	<b>1,135</b>	<b>-31.1%</b>
Dossier Fees	0	2	-100.0%	0	2	-100.0%
Royalty Income	74	140	-47.1%	175	296	-40.9%
Net Gain on foreign currency transactions and translation (Refer Note below)	175	17	912.2%	175	476	-63.1%
Others	236	192	23.3%	431	361	19.6%

Note : Apart from this gain, there was a net loss of Rs. 178 Mio. in Q2 13-14 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and Sales. Thus, on aggregate level, there was a loss of Rs. 3 Mio. on operating transactions (above EBIDTA line) in Q2 13-14 vs loss of Rs. 624 Mio. in Q2 12-13. See details below for more clarity.

Rs. Mio.	Q2 13-14	Q2 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Other Income</b>	<b>122</b>	<b>65</b>	<b>89.5%</b>	<b>248</b>	<b>160</b>	<b>55.1%</b>
Interest & Dividend income	85	72	18.5%	179	140	28.0%
Profit on sale of investments	9	4	112.2%	37	6	551.2%
Profit on sale of assets	0	-9	100.0%	0	0	
Others	28	-3	1095.9%	32	14	128.3%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q2 13-14	Q2 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>3</b>	<b>624</b>	<b>-99.5%</b>	<b>-245</b>	<b>184</b>	<b>-233.2%</b>
a. Included in other income	-175	-17	-910.0%	-175	-476	63.2%
b. Included in sales	271			271		
c. Included in cost of goods	-58	641	-109.0%	-341	660	-151.7%
d. Included in other expenses	-35	0	-45294.7%	0		
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>-126</b>	<b>133</b>	<b>-194.4%</b>	<b>-144</b>	<b>404</b>	<b>-135.7%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>-123</b>	<b>757</b>	<b>-116.2%</b>	<b>-389</b>	<b>588</b>	<b>-166.2%</b>

Details of R&D Expenses

Rs. Mio.	Q2 13-14	Q2 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>1,288</b>	<b>1,172</b>	<b>10%</b>	<b>2,341</b>	<b>2,044</b>	<b>15%</b>

Consolidated Capex for Apr-Sep 13

Rs. 4171  
Mio.

R&D capex included in above for Apr-Sep 13 :

Rs. 43  
Mio.